Physician profile
Horng-Chyi Richard Lai
NPI 1528385598
$449,385.53
in general payments reported to CMS, 2019-2025
37 companies · $95K in 2025
The $95K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $19K · 2021: $40K · 2022: $78K · 2023: $120K · 2024: $83K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Honoraria: $53K · Travel and Lodging: $44K · Food and Beverage: $16K · Consulting Fee: $11K · Education: $267 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,820.00 |
| Honoraria | $52,893.75 |
| Travel and Lodging | $44,155.27 |
| Food and Beverage | $15,852.69 |
| Consulting Fee | $11,407.50 |
| Education | $267.18 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $146,631.93 | 2019-2025 | Krystexxa, Otezla, Tavneos |
| Horizon Therapeutics Plc | $122,334.53 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $64,626.64 | 2020-2025 | Acthar |
| Abbvie INC. | $51,650.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $24,706.67 | 2019-2025 | Benlysta |
| Pfizer INC. | $8,942.63 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,891.52 | 2019-2025 | Spevigo, Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $7,424.30 | 2020-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $6,187.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,362.67 | 2020-2025 | |
| Celgene Corporation | $1,252.46 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $792.74 | 2022-2025 | Saphnelo, Breztri |
| Ucb, INC. | $574.27 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $447.87 | 2020-2024 | Taltz, Olumiant |
| Actelion Pharmaceuticals US, INC. | $440.55 | 2021-2025 | Opsumit, Uptravi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $431.36 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genentech USA, INC. | $374.29 | 2019-2023 | Ocrevus |
| Ani Pharmaceuticals, INC. | $290.15 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $278.07 | 2022 | |
| Genzyme Corporation | $218.43 | 2021-2025 | |
| Octapharma USA, INC. | $192.38 | 2022-2023 | Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals, Ltd. | $183.22 | 2023 | Arcalyst |
| Radius Health, INC. | $173.37 | 2019-2025 | Tymlos |
| Biogen, INC. | $166.62 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $129.18 | 2021-2024 | Lupkynis |
| Sobi, INC | $116.13 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $105.39 | 2022 | |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $90.87 | 2021-2023 | |
| Sandoz INC. | $73.79 | 2023-2025 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $66.67 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $45.60 | 2024 | Arcalyst |
| Mylan Institutional INC. | $20.46 | 2023 | Hulio |
| Alnylam Pharmaceuticals INC. | $19.69 | 2023 | Amvuttra |
| Fresenius Kabi USA, LLC | $14.93 | 2023 | Idacio |
| Grifols USA, LLC | $14.61 | 2022 | |
| Bioventus LLC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Horng-Chyi Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.